1999年7月
Tumor vascular targeting using a tumor-tissue endothelium-specific monoclonal antibody as an effective strategy for cancer chemotherapy
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- 巻
- 260
- 号
- 2
- 開始ページ
- 346
- 終了ページ
- 350
- 記述言語
- 英語
- 掲載種別
- DOI
- 10.1006/bbrc.1999.0647
- 出版者・発行元
- ACADEMIC PRESS INC
In this study, we attempted to develop tumor vascular targeting with a tumor tissue endothelium-specific monoclonal antibody. TES-23, which strongly and selectively recognizes tumor tissue endothelial cells, was chemically conjugated with Neocarzinostatin (NCS), and the anti-tumor effect was examined. The immunoconjugate, TES-23-NCS, showed, through the use of tumor hemorrhagic necrosis, a marked antitumor effect on KMT-17 tumors in rats at a dosage of 17 mu g/kg (NCS equivalent) without any side effects, probably due to specific turner vascular injury. By contrast, TES-23 alone (107 mu g/kg), NCS alone (17 mu g/kg), and Mopc-NCS (Mopc, 107 mu g/kg; NCS, 17 mu g/kg), the immunoconjugate of control antibody, did not have any anti-tumor activities. By tissue distribution analysis, TES-23 and TES-23-NCS showed high accumulation in KMT-17 tumors 1 h after intravenous administration. Moreover TES-23 also accumulated in Sarcoma-180 tumors in mice 1 h after intravenous administration. These results suggest that TES-23 may be a candidate for a potential tumor vascular targeting agent that is applicable to a wide variety of tumor types. (C) 1999 Academic Press.
- リンク情報
-
- DOI
- https://doi.org/10.1006/bbrc.1999.0647
- CiNii Articles
- http://ci.nii.ac.jp/naid/80011185150
- PubMed
- https://www.ncbi.nlm.nih.gov/pubmed/10403773
- Web of Science
- https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=JSTA_CEL&SrcApp=J_Gate_JST&DestLinkType=FullRecord&KeyUT=WOS:000081443800009&DestApp=WOS_CPL
- ID情報
-
- DOI : 10.1006/bbrc.1999.0647
- ISSN : 0006-291X
- CiNii Articles ID : 80011185150
- PubMed ID : 10403773
- Web of Science ID : WOS:000081443800009